KR20140043075A - 사이토카인 활성의 조절 방법 - Google Patents

사이토카인 활성의 조절 방법 Download PDF

Info

Publication number
KR20140043075A
KR20140043075A KR1020137030512A KR20137030512A KR20140043075A KR 20140043075 A KR20140043075 A KR 20140043075A KR 1020137030512 A KR1020137030512 A KR 1020137030512A KR 20137030512 A KR20137030512 A KR 20137030512A KR 20140043075 A KR20140043075 A KR 20140043075A
Authority
KR
South Korea
Prior art keywords
hydroxy
hydrogen
substituted
mono
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137030512A
Other languages
English (en)
Korean (ko)
Inventor
류지 우에노
Original Assignee
수캄포 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수캄포 아게 filed Critical 수캄포 아게
Publication of KR20140043075A publication Critical patent/KR20140043075A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137030512A 2011-04-19 2012-04-18 사이토카인 활성의 조절 방법 Ceased KR20140043075A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161476992P 2011-04-19 2011-04-19
US61/476,992 2011-04-19
US201161489516P 2011-05-24 2011-05-24
US61/489,516 2011-05-24
US201161537305P 2011-09-21 2011-09-21
US61/537,305 2011-09-21
US201161548458P 2011-10-18 2011-10-18
US61/548,458 2011-10-18
PCT/JP2012/061004 WO2012144649A1 (en) 2011-04-19 2012-04-18 Method for modulating cytokine activity

Publications (1)

Publication Number Publication Date
KR20140043075A true KR20140043075A (ko) 2014-04-08

Family

ID=47021806

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137030512A Ceased KR20140043075A (ko) 2011-04-19 2012-04-18 사이토카인 활성의 조절 방법

Country Status (13)

Country Link
US (1) US20120270945A1 (enExample)
EP (1) EP2699244A4 (enExample)
JP (1) JP2014511825A (enExample)
KR (1) KR20140043075A (enExample)
CN (2) CN103781482A (enExample)
AU (2) AU2012246999A1 (enExample)
BR (1) BR112013026644A2 (enExample)
CA (1) CA2831869A1 (enExample)
IL (1) IL228700A0 (enExample)
MX (1) MX2013012251A (enExample)
RU (1) RU2013151166A (enExample)
TW (1) TW201247615A (enExample)
WO (1) WO2012144649A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0708362A2 (pt) * 2006-02-28 2011-05-24 Sucampo Ag método e composição para o tratamento de doença pulmonar obstrutiva crÈnica
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment
WO2015049876A1 (ja) * 2013-10-04 2015-04-09 国立大学法人東北大学 腎機能障害の予防又は改善剤
US20160120840A1 (en) * 2014-10-30 2016-05-05 Sucampo Ag Method and composition for treating nonerosive reflux disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
ATE148344T1 (de) * 1990-04-27 1997-02-15 R Tech Ueno Ltd Verwendung von 15-dehydroxy-16-oxoprostaglandin bei der behandlung von allergischen erkrankungen
JPH0770054A (ja) * 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JPH1029942A (ja) * 1996-04-02 1998-02-03 Yoichi Ichikawa 慢性関節リウマチ治療剤
EP1841433B1 (en) * 2005-01-27 2011-11-30 Sucampo AG Composition for treating central nervous system disorders
AR055038A1 (es) * 2005-03-04 2007-08-01 Sucampo Ag Metodo y compuesto para tratar enfermedades vasculares perifericas
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
KR20140069182A (ko) * 2005-04-12 2014-06-09 수캄포 아게 위장 장애 치료를 위한 프로스타글란딘 화합물과 양성자 펌프 억제제의 병용
BRPI0708362A2 (pt) * 2006-02-28 2011-05-24 Sucampo Ag método e composição para o tratamento de doença pulmonar obstrutiva crÈnica
EP2147672A4 (en) * 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST
EP2305304A4 (en) * 2008-04-28 2011-08-10 Nat University Corp Hamamatsu University School Of Medicine IMMUNOSTIMULATOR WITH EP1 AGONIST
JP2011032262A (ja) * 2009-06-30 2011-02-17 Sucampo Ag Ｎｓａｉｄの長期使用のための医薬組成物
JP5755750B2 (ja) * 2010-10-15 2015-07-29 サイノファーム （クンシャン） バイオケミカル テクノロジ カンパニー リミテッド ルビプロストンの調製方法

Also Published As

Publication number Publication date
RU2013151166A (ru) 2015-05-27
CA2831869A1 (en) 2012-10-26
EP2699244A4 (en) 2014-10-22
WO2012144649A1 (en) 2012-10-26
BR112013026644A2 (pt) 2016-12-27
NZ616027A (en) 2015-09-25
AU2012246999A1 (en) 2013-10-17
US20120270945A1 (en) 2012-10-25
MX2013012251A (es) 2014-01-20
CN107028952A (zh) 2017-08-11
EP2699244A1 (en) 2014-02-26
AU2017203276A1 (en) 2017-06-08
JP2014511825A (ja) 2014-05-19
TW201247615A (en) 2012-12-01
IL228700A0 (en) 2013-12-31
CN103781482A (zh) 2014-05-07

Similar Documents

Publication Publication Date Title
KR101920197B1 (ko) 말초 혈관 질환 치료를 위한 방법 및 조성물
KR20140043075A (ko) 사이토카인 활성의 조절 방법
US5252605A (en) Promotion of wound-healing with 15-keto-prostaglandin compounds
US5164415A (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
US5346921A (en) Treatment of inflammation with 15-keto-prostaglandin compounds
KR101354771B1 (ko) 중추 신경계 질환 치료를 위한 방법 및 조성물
WO2015050277A1 (en) Selective tumor treatment
KR20120018158A (ko) 황반변성을 치료하기 위한 방법 및 조성물
JP6193230B2 (ja) 統合失調症の処置方法
US20160120840A1 (en) Method and composition for treating nonerosive reflux disease
KR20120081139A (ko) 종양 치료용 약제학적 조합물
US20120277299A1 (en) Method for modulating ion transporter
NZ616027B2 (en) Method for modulating cytokine activity
JP2016521678A (ja) 幹細胞の腫瘍形成能の抑制方法
JPWO2012176792A1 (ja) 炎症性疾患、アレルギー性疾患および自己免疫疾患用途のための医薬組成物
HK1196278A (en) Method for treating schizophrenia

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131118

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170418

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180201

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180406

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180201

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I